Genomic Alterations and MYD88MUT Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

(2019) Anas Younes et al.   Lancet Haematology

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

(2019) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

MYD88 Mutations and Sensitivity to Ibrutinib Therapy

(2018) Y. Lynn Wang   JOURNAL OF MOLECULAR DIAGNOSTICS

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

(2018) Bjoern Chapuy et al.   NATURE MEDICINE

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

(2018) Roland Schmitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Technical Validation of a Next-Generation Sequencing Assay for Detecting Clinically Relevant Levels of Breast Cancer–Related Single-Nucleotide Variants and Copy Number Variants Using Simulated Cell-Free DNA

(2017) Xin Yang et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis

(2017) Ju-Han Lee et al.   Scientific Reports

Diffuse Large B-Cell Lymphoma: Current Strategies and Future Directions

(2017) Jennifer L. Cultrera et al.   Cancer Control

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases

(2016) Sydney Dubois et al.   CLINICAL CANCER RESEARCH

MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome

(2016) J. Rovira et al.   CLINICAL CANCER RESEARCH

The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies

(2016) Sydney Dubois et al.   Expert Review of Hematology

Targetable genetic features of primary testicular and primary central nervous system lymphomas

(2015) B. Chapuy et al.   BLOOD

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

(2015) Wyndham H Wilson et al.   NATURE MEDICINE

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma

(2014) C Fernández-Rodríguez et al.   LEUKEMIA

Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing

(2013) R. D. Morin et al.   BLOOD

Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma

(2013) Elodie Bohers et al.   GENES CHROMOSOMES & CANCER

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

(2013) Kristian Cibulskis et al.   NATURE BIOTECHNOLOGY

Genetic heterogeneity of diffuse large B-cell lymphoma

(2013) Jenny Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites

(2013) W Kraan et al.   Blood Cancer Journal

CONTRA: copy number analysis for targeted resequencing

(2012) Jason Li et al.   BIOINFORMATICS

Subtype distribution of lymphomas in Southwest China: Analysis of 6,382 cases using WHO classification in a single institution

(2011) Qun-Pei Yang et al.   Diagnostic Pathology

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

(2011) Ryan D. Morin et al.   NATURE

Analysis of the coding genome of diffuse large B-cell lymphoma

(2011) Laura Pasqualucci et al.   NATURE GENETICS

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

(2010) A. McKenna et al.   GENOME RESEARCH

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE